Entering text into the input field will update the search result below

ARCT Arcturus Therapeutics Holdings Inc.
Stock Price & Overview

$23.94-0.30 (-1.24%)4:00 PM 11/30/23
NASDAQ | $USD | Post-Market: $22.24 -1.70 (-7.10%) 6:23 PM

Charts

FFO (FWD)
PE
Div Rate (TTM)
Yield (TTM)
Short Interest
Market Cap
Volume
Prev. Close

Quant Ranking

Ratings Summary

SA Analysts
Wall Street
Quant
Now3M ago6M ago
Valuation
-Rating: Not Covered
Growth
-Rating: Not Covered
Profitability
-Rating: Not Covered
Momentum
-Rating: Not Covered
Revisions
-Rating: Not Covered

See ARCT ratings with Premium.

People Also Follow

Company Profile

Arcturus Therapeutics Holdings Inc. logo
Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. The company was founded in 2013 and is headquartered in San Diego, California.
Employees
170
Founded
2013
Address
  • 10628 Science Center Drive
  • Suite 250
  • San Diego, CA, 92121
  • United States
Phone Number
858 900 2660
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.